7 mei 2012: In onderstaand artikel zijn enkele links hersteld en informatie toegevoegd. Als u hier klikt is een volledig studierapport gratis in te zien over de rol van Her2-Neu expressie bij alvleesklierkanker 

HER2/neu Expression and Gene Alterations in Pancreatic Ductal Adenocarcinoma: A Comparative Immunohistochemistry and Chromogenic in Situ Hybridization Study Based on Tissue Microarrays and Computerized Image Analysis

14 mei 2009:  Bron: 1: Cancer Sci. 2009 Apr 21. [Epub ahead of print]Click here to read  

HER2-overexpressie wordt in verband gebracht met invloed op klinische resultaten bij verschillende vaste tumoren, zoals borstkanker. Echter, de correlatie tussen HER2-overexpressie en overleving bij alvleesklierkanker blijft onduidelijk. De invloed van HER2-overexpressie op overleving bij operatieve en curatieve ductaal alvleesklierkanker is nu onderzocht. Van alle operatief verwijderde tumoren werd de Her2Neu expressie gemeten en daarop getoestst aan overlevingskansen voor de patiënten. En daaruit blijkt dat bij alvleesklierkankerpatienten die een verhoogde Her2-Neu expressie hadden de prognose op overleven significant slechter was. (Mediane overlevingstijd, 14,7 versus 20,7 maanden respectievelijk; P = 0.0078 op de log-rank test).

Tweeëntwintig gevallen (17,1%) had een score van 0, 28 gevallen (21,7%) had een score van 1 +, 41 gevallen (31,8%) had een score van 2 +, en 38 gevallen (29,4%) hadden een score van 3 +.
HER2-overexpressie (score 2 + of 3 +) werd waargenomen in 79 gevallen (61,2%). Patiënten met HER2-overexpressie tumoren hadden aanzienlijk kortere overleving dan die met HER2 normale expressie (score 0 of 1 +) tumoren (mediane overlevingstijd, 14,7 versus 20,7 maanden respectievelijk; P = 0.0078 op de log-rank test). Op multivariate survival analyse bleek HER2-overexpressie een onafhankelijke prognostische factor (hazard ratio 1,806; P = 0,0258). Een aanzienlijk percentage van de alvleesklierkanker bleek HER2-overexpressie te hebben en de overexpressie van deze tyrosine kinase receptor bleek een onafhankelijke factor te zijn voor een slechtere prognose.

Deze resultaten moeten aanleiding zijn verder onderzoek van behandelingen met behulp van nieuwe moleculaire middelen gericht tegen HER2 eiwit ter verbetering van de overleving van pancreaskanker patiënten te initieren. (Cancer Sci 2009).

Als u hier klikt kunt u het volledige studierapport tegen betaling inzien. Hier het abstract van de studie. Onderaan een referentielijst van studies betreffende dit onderwerp.

HER2 overexpression correlates with survival after curative resection of pancreatic cancer.

Cancer Sci. 2009 Jul;100(7):1243-7. Epub 2009 Apr 21.
Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K.

Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.

HER2 overexpression has been linked to clinical outcomes in several solid tumors, such as breast cancer. However, the correlation between HER2 overexpression and survival in pancreatic carcinoma remains unclear. The impact of HER2 overexpression on survival in pancreatic ductal cancer was examined. Immunohistochemical staining of 129 pancreatic cancers without hematogenous metastases or peritoneal dissemination treated by macroscopically curative resection were analyzed in association with survival data. To determine HER2 overexpression in this pancreatic cancer series, the polyclonal antibody included in HercepTest, which is used worldwide for clinical examination of HER2 overexpression in breast cancer, was used. Immunoreactivity was classified according to the scale presented in the HercepTest Scoring Guidelines. Twenty-two cases (17.1%) had a score of 0, 28 cases (21.7%) had of a score of 1+, 41 cases (31.8%) had a score of 2+, and 38 cases (29.4%) had a score of 3+. Therefore, HER2 overexpression (score 2+ or 3+) was observed in 79 cases (61.2%). Patients with HER2 overexpression tumors had significantly shorter survival times than those with HER2 normal expression (score 0 or 1+) tumors (median survival time, 14.7 vs 20.7 months, respectively; P = 0.0078 on the log-rank test). On multivariate survival analysis, HER2 overexpression remained an independent prognostic factor (hazard ratio, 1.806; P = 0.0258). A significant percentage of pancreatic cancers were demonstrated to have HER2 overexpression, and overexpression of this tyrosine kinase receptor proved to be an independent factor for a worse prognosis. These results should encourage further investigation of treatments using new molecular targeting agents against HER2 protein to improve the survival of pancreatic cancer patients. (Cancer Sci 2009).

PMID: 19432892 [PubMed - as supplied by publisher]

References

  • 1
    Coussens L, Yang-Feng TL, Liao YC et al . Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–9.
  • 2
    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Eng J Med 2008; 358: 1160–74.
  • 3
    Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259–69.
  • 4
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the Her2/neu oncogene. Science 1987; 235: 177–82.
  • 5
    Slamon DJ, Godolphin W, Jones LA et al . Studies of the Her2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12.
  • 6
    Alberton DG, Collins C, McComick Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003; 34: 369–76.
  • 7
    Wang S, Saboorian HM, Frenkel EP et al . Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002; 15: 137–45.
  • 8
    Edgerton SM, Moore D 2nd, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morph 2003; 11: 214–21.
  • 9
    Kern JA, Schwartz DA, Nordberg JE et al . p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184–91.
  • 10
    Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 474–9.
  • 11
    Park DII, Yun JW, Park JH et al . HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371–9.
  • 12
    Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 1995; 17: 15–21.
  • 13
    Yamanaka Y, Friess H, Kobrin MS et al . Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993; 24: 1127–34.
  • 14
    Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res 2002; 22: 1593–7.
  • 15
    SobinLH, WitterkindC, eds. TNM. Classification of Malignant Tumors, 6th edn. New York: Wiley-Liss, 2002: 93–6.
  • 16
    Day JD, Digiuseppe JA, Yeo C et al . Immunohistochemical evaluation of HER-2/new expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; 27: 119–24.
  • 17
    Saxby AJ, Nielsen A, Scarlett CJ et al . Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 2005; 29: 1125–34.
  • 18
    Mass RD, Press MF, Anderson S et al . Evaluation of clinical outcomes according to Her2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240–6.
  • 19
    Petit AM, Rak J, Hung MC et al . Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523–30.
  • 20
    Stoecklein NH, Luebke AM, Erbersdobler A et al . Copy number of chromosome 17 but not her2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2004; 22: 4737–45.
  • 21
    Vogel CL, Cobleign MA, Tripathy D et al . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 overexpression metastatic breast cancer. J Clin Oncol 2002; 20: 719–26.
  • 22
    Kimura K, Sawada T, Komatsu M et al . Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006; 12: 4925–32.
  • 23
    Safran H, Iannitti D, Ramanathan R et al . Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22: 706–12.
  • 24
    Rusnak DW, Lackey K, Affleck K et al . The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85–94.
  • 25
    Geyer CE, Forster J, Lindquist D et al . Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Eng J Med 2006; 355: 2733–43.

Her2-Neu expressie, pancreaskanker, alvleesklierkanker, personalised medicine


Plaats een reactie ...

Reageer op "Personalised medicine: Operabele alvleesklierkankerpatienten met overexpressie van Her2-Neu hebben significant kortere overlevingstijd dan alvleesklierkankerpatienten met normale Her2-Neu expressiewaarden."


Gerelateerde artikelen
 

Gerelateerde artikelen

Personalised medicine op basis >> Regulier - alvleesklierkanker >>